FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022245544> ?p ?o ?g. }

• W2022245544 abstract "The discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK-rearranged NSCLC in 2011 represents a landmark in the development of targeted oncology therapy. The approval of crizotinib was accompanied simultaneously by the approval of approval of the Vysis (Abbott Molecular) break-apart fluorescence in situ hybridization test as the companion diagnostic (CDx) test to detect ALK rearrangement. Pfizer, the manufacturer of crizotinib, sponsored the screening of thousands of patients and the standardization of the ALK FISH test as part of the approval process for crizotinib, a first in class ALK inhibitor. Many pharmaceutical companies are now using the FDA-approved ALK FISH assay to enroll patients onto trials for their own respective ALK inhibitors. In essence they are “piggybacking” on the FDA-approved ALK FISH assay without having to pay for the development of a CDx, nor screening for ALK-rearranged NSCLC patients in the protocols because screening for ALK rearrangement is now the standard of care in NSCLC after the approval of crizotinib. Since 2007, rearrangement in more RTKs such as ROS1, RET, AXL, PDGFR-α, and NTRK1 have been discovered in NSCLC but the incidence of each subtype of RTK-rearranged NSCLC is quite rare. Crizotinib has now demonstrated significant clinical activity in ROS1-rearranged NSCLC patients. Whether crizotinib will gain official FDA approval for use in ROS1-rearranged NSCLC, on the other hand, remains unclear as there is no test for ROS1 rearrangement currently being developed to support US FDA approval as a CDx. This may be due in part to the fact that the full cost associated with the development of a pre-market approved (PMA)-approved CDx must be borne by the company seeking the first drug approval in a new indication. Given the low incidence of ROS1 rearrangement in NSCLC, and the availability of crizotinib in most countries" @default.
• W2022245544 created "2016-06-24" @default.
• W2022245544 creator A5032293215 @default.
• W2022245544 creator A5034739279 @default.
• W2022245544 creator A5044361715 @default.
• W2022245544 creator A5052923575 @default.
• W2022245544 creator A5087923582 @default.
• W2022245544 date "2014-04-01" @default.
• W2022245544 modified "2023-10-02" @default.
• W2022245544 title "Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?" @default.
• W2022245544 cites W1508955841 @default.
• W2022245544 cites W1594510878 @default.
• W2022245544 cites W1639582946 @default.
• W2022245544 cites W1968209756 @default.
• W2022245544 cites W1970888488 @default.
• W2022245544 cites W1971870374 @default.
• W2022245544 cites W1975396905 @default.
• W2022245544 cites W1975784282 @default.
• W2022245544 cites W1981316461 @default.
• W2022245544 cites W1995082806 @default.
• W2022245544 cites W2010561682 @default.
• W2022245544 cites W2012141473 @default.
• W2022245544 cites W2013022837 @default.
• W2022245544 cites W2022319775 @default.
• W2022245544 cites W2050249255 @default.
• W2022245544 cites W2064378491 @default.
• W2022245544 cites W2071480068 @default.
• W2022245544 cites W2080899976 @default.
• W2022245544 cites W2085402944 @default.
• W2022245544 cites W2085794439 @default.
• W2022245544 cites W2090226388 @default.
• W2022245544 cites W2091493266 @default.
• W2022245544 cites W2093585687 @default.
• W2022245544 cites W2097395369 @default.
• W2022245544 cites W2098599074 @default.
• W2022245544 cites W2132578211 @default.
• W2022245544 cites W2133668831 @default.
• W2022245544 cites W2134820929 @default.
• W2022245544 cites W2137713702 @default.
• W2022245544 cites W2145247101 @default.
• W2022245544 cites W2149592447 @default.
• W2022245544 cites W2150611307 @default.
• W2022245544 cites W2151601609 @default.
• W2022245544 cites W2154493372 @default.
• W2022245544 cites W2155591233 @default.
• W2022245544 cites W2166292499 @default.
• W2022245544 cites W2168404690 @default.
• W2022245544 cites W2168691181 @default.
• W2022245544 cites W2169013957 @default.
• W2022245544 cites W2169691338 @default.
• W2022245544 cites W2174680146 @default.
• W2022245544 doi "https://doi.org/10.3389/fonc.2014.00058" @default.
• W2022245544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3978317" @default.
• W2022245544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24744988" @default.
• W2022245544 hasPublicationYear "2014" @default.
• W2022245544 type Work @default.
• W2022245544 sameAs 2022245544 @default.
• W2022245544 citedByCount "23" @default.
• W2022245544 countsByYear W20222455442013 @default.
• W2022245544 countsByYear W20222455442014 @default.
• W2022245544 countsByYear W20222455442015 @default.
• W2022245544 countsByYear W20222455442016 @default.
• W2022245544 countsByYear W20222455442019 @default.
• W2022245544 countsByYear W20222455442020 @default.
• W2022245544 countsByYear W20222455442021 @default.
• W2022245544 crossrefType "journal-article" @default.
• W2022245544 hasAuthorship W2022245544A5032293215 @default.
• W2022245544 hasAuthorship W2022245544A5034739279 @default.
• W2022245544 hasAuthorship W2022245544A5044361715 @default.
• W2022245544 hasAuthorship W2022245544A5052923575 @default.
• W2022245544 hasAuthorship W2022245544A5087923582 @default.
• W2022245544 hasBestOaLocation W20222455441 @default.
• W2022245544 hasConcept C104317684 @default.
• W2022245544 hasConcept C117643217 @default.
• W2022245544 hasConcept C121608353 @default.
• W2022245544 hasConcept C126322002 @default.
• W2022245544 hasConcept C143998085 @default.
• W2022245544 hasConcept C2775999482 @default.
• W2022245544 hasConcept C2776232967 @default.
• W2022245544 hasConcept C2776256026 @default.
• W2022245544 hasConcept C2777542201 @default.
• W2022245544 hasConcept C2778347629 @default.
• W2022245544 hasConcept C2778820342 @default.
• W2022245544 hasConcept C2779220645 @default.
• W2022245544 hasConcept C2779422266 @default.
• W2022245544 hasConcept C2779750558 @default.
• W2022245544 hasConcept C2780416959 @default.
• W2022245544 hasConcept C2781182431 @default.
• W2022245544 hasConcept C2992511266 @default.
• W2022245544 hasConcept C30481170 @default.
• W2022245544 hasConcept C502942594 @default.
• W2022245544 hasConcept C55493867 @default.
• W2022245544 hasConcept C71924100 @default.
• W2022245544 hasConcept C86803240 @default.
• W2022245544 hasConceptScore W2022245544C104317684 @default.
• W2022245544 hasConceptScore W2022245544C117643217 @default.
• W2022245544 hasConceptScore W2022245544C121608353 @default.
• W2022245544 hasConceptScore W2022245544C126322002 @default.
• W2022245544 hasConceptScore W2022245544C143998085 @default.
• W2022245544 hasConceptScore W2022245544C2775999482 @default.

• next